The Matrix Metalloproteinase 9 pipeline drugs market research report outlays comprehensive information on the Matrix Metalloproteinase 9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Matrix Metalloproteinase 9 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Central Nervous System, Oncology, Dermatology, and Gastrointestinal which include the indications Epilepsy, Neuropathic Pain (Neuralgia), Oncology, Melanoma, Wounds, Atopic Dermatitis (Atopic Eczema), Crohn’s Disease (Regional Enteritis), and Inflammatory Bowel Disease. It also reviews key players involved in Matrix Metalloproteinase 9 targeted therapeutics development with respective active and dormant or discontinued products.

The Matrix Metalloproteinase 9 pipeline targets constitutes close to 20 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 12, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 5 molecule.

Matrix Metalloproteinase 9 overview

Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.

For a complete picture of Matrix Metalloproteinase 9’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.